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Abstract 
Background: Acinetobacter baumannii is a nosocomial pathogen which is establishing as a major cause of morbid-
ity and mortality within the healthcare community. The success of this pathogen is largely due to its ability to rapidly 
gain resistance to antimicrobial therapies and its capability to persist in an abiotic environment through the produc-
tion of a biofilm. Our tertiary-care hospital has showed high incidence of carbapenem-resistant Acinetobacter bau-
mannii (CRAB) isolates.
Methods: In this study we explore both genotypic and phenotypic properties of 26 CRAB isolates: 16 isolates were 
collected from January 2010 to March 2011, and 10 were collected between February and May 2015.
Results: We determined that all 26 CRAB isolates possessed multiple β-lactamase genes, including genes from 
Groups A, C, and D. Specifically, 42% of the isolates possesses the potentially plasmid-borne genes of OXA-23-like or 
OXA-40-like β-lactamase. The presence of mobile gene element integron cassettes and/or integrases in 88% of the 
isolates suggests a possible mechanism of dissemination of antibiotic resistance genes. Additionally, the location of 
insertion sequence (IS) ISAba1 in promotor region of of the OXA-51-like, ADC-7, and ampC genes was confirmed. 
Multilocus sequence typing (MLST) demonstrated that all 26 CRAB isolates were either sequence type (ST)-229 or 
ST-2. Interestingly, ST-2 went from being the minority CRAB strain in the 2010–2011 isolates to the predominant strain 
in the 2015 isolates (from 32 to 90%). We show that the ST-2 strains have an enhanced ability to produce biofilms in 
comparison to the ST-229 strains, and this fact has potentially led to more successful colonization of the clinical envi-
ronment over time.
Conclusions: This study provides a longitudinal genetic and phenotypic survey of two CRAB sequence types, and 
suggests how their differing phenotypes may interact with the selective pressures of a hospital setting effecting strain 
dominance over a 5-year period.
Keywords: Acinetobacter baumannii, β-lactamase, Biofilm, Carbapenem resistance, Colonization, CRAB, Integrase, 
Integron cassette, Multiple drug resistance, Multilocus sequence typing, MLST, OXA-51, OXA-23, OXA-40, Plasmid
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Background
Acinetobacter baumannii is an opportunistic pathogen 
that causes a variety of nosocomial infections resulting 
in considerable morbidity and mortality, and presents 
a particular threat to intensive care unit (ICU) patients 
[1–4]. The number of A. baumannii infections has been 
increasing globally over the past three decades; particu-
larly with regard to infections involving multi-drug resist-
ant (MDR) isolates. The rise of MDR bacterial strains is a 
major cause for concern among healthcare professionals 
and is prompting changes in both antibiotic regiments 
and hospital disinfection techniques [5–10]. Genomic 
studies exploring outbreaks of MDR A. baumannii from 
geographic regions distant from one another shows a 
high degree of similarity among strains, indicating that 
most outbreaks may be due to a limited number of clonal 
lines [11].
The ability of A. baumannii to rapidly gain resistance 
to antimicrobial compounds is an important population-
level virulence factor [12] for the successful dissemination 
of the organism within and among health-care facilities 
[13, 14]. Most strains of A. baumannii are innately resist-
ant to several classes of antibiotics such as first- and sec-
ond-generation cephalosporins, chloramphenicol, and 
aminopenicillins; in addition, the ability to both accept 
exogenous genetic material and overexpress endogenous 
resistance genes has quickly resulted in the appearance 
of the MDR phenotype within multiple clonal lineages [6, 
15]. Historically the drug of choice to treat severe A. bau-
mannii infections has been carbapenems, the clinical use 
of both meropenem and imipenem increased dramatically 
in the last 15 years to treat newly emerging MDR strains 
[1]. Likely as a result of this selective pressure carbape-
nem-resistant Acinetobacter baumannii (CRAB) strains 
are being reported with greater frequency.
In addition to antibiotic resistance, the ability to adhere 
and produce biofilm on both biotic and abiotic surfaces 
has been shown to be a virulence factor in many clinical 
isolates of A. baumannii and other bacterial pathogens 
[16–19]. The ability of clinical isolates to adhere to lung 
epithelial cells which is a critical step in the establish-
ment of lung infections, and have also been documented 
[20–22]. The organism survives even on abiotic surfaces 
for months, and numerous retrospective epidemiological 
studies have shown its ability to colonize medical equip-
ment, furniture, and healthcare personnel; this phenom-
enon provides the organism the capability of causing 
outbreaks both within and among medical institutions 
[23–28].
In the present study, we characterize the carbapenem 
resistance genotypic profile, as well as the colonization-
associated phenotypes of 26 CRAB isolates, collected 
between 2010 and 2015, from a tertiary care hospital 
in Philadelphia, Pennsylvania. By analyzing these data, 
we aimed to determine if there was a temporal trend in 
resistance or colonization among these clinical isolates.
Methods
Bacterial isolates and reference strains
This study included 26 clinical isolates of carbapenem-
resistant [minimum inhibitory concentration of mero-
penem (MIC)  ≥  8  mg/L] isolated from Hahnemann 
Hospital of Drexel University College of Medicine, 
Philadelphia, PA. Sixteen of the isolates were collected 
between 2010 and 2011 and were previously partially 
described by Sen and Joshi [29], (old isolates) and 10 iso-
lates were collected in 2015 (New Isolates) which have 
not been described to date. The isolates were randomly 
selected, based on their MIC to meropenem. A. bau-
mannii isolates were identified using the Vitek2 system 
(BioMerieux Vitek Systems Inc., USA), and confirmed by 
a molecular technique of OXA-51 PCR. Clinical Labora-
tory Standards Institute (CLSI)—recommended quality 
control (QC) strains were used as reference strains when 
necessary. QC strains included: A. baumannii ATCC 
19606, A. baumannii ATCC 17978; Escherichia coli 
ATCC-BAA-2452, NCTC 13476; Klebsiella pneumoniae 
ATCC-BAA-2146, K. pneumoniae ATCC-BAA-1705, 
K. pneumoniae NCTC13440, and Enterobacter cloa-
cae NCTC 13464. Additional file  1: Table S1 shows the 
QC strains and the reference gene for which they were 
used. The study was approved by the Institutional Review 
Board (IRB) of Drexel University, and a waiver granted.
Determination of minimum inhibitory concentration (MIC)
Carbapenem MIC results were obtained for each CRAB 
isolate using the VITEK 2 system and the results were 
confirmed by broth microdilution. All clinical break-
points recommendations and broth microdilution 
protocols were followed as per Clinical Laboratory 
Standards Institute (CLSI) guidelines [30]. The antimi-
crobial agents tested were ampicillin/sulbactam, imipe-
nem, meropenem, amikacin, levofloxacin, gentamicin, 
cefepime, tobramycin, trimethoprim/sulfamethoxazole 
and piperacillin. In routine, our hospital laboratory does 
not include and report polymyxin and tigecycline for 
this organism, and hence these agents were not included 
to study panel.
Polymerase chain reaction (PCR) Amplification and DNA 
Sequencing
Using DNeasy Blood and Tissue kit (Qiagen, Valencia, 
CA), genomic DNA was isolated from bacterial cells. All 
PCR primers targeting resistance genes and mobile ele-
ments used in this study are listed in Additional file  2: 
Table S2. PCR was performed using Thermo Scientific 
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Dream Taq Green PCR Master Mix (Thermo-Fisher 
Scientific, Inc, Waltham, MA) using conditions speci-
fied by the reference sources. The isolates were tested for 
each target gene two–four times. Negative controls were 
included with every PCR setup to monitor for carryo-
ver [31] and rule out nonspecific amplification. Appro-
priate positive control strains were used to confirm the 
validity of each PCR primer pair (Additional file 1: Table 
S1). Wherever an appropriate QC strain for a particu-
lar gene was unavailable the amplicon present with the 
approximate size of the predicted product was purified 
using described method and sequences analyzed, and 
gene identifications were made using NCBI nucleotide 
BLAST tool (https://blast.ncbi.nlm.nih.gov/Blast/). The 
presence of IS elements (ISAba1) upstream of target 
genes following the method described by Sen and Joshi 
[29].
Meropenem‑EDTA double disk synergy test (DDS)
DDS was performed as described previously by Yong 
et al. using 0.5 McFarland standards, and disks contain-
ing Meropenem (10 µg) alone; Meropenem (10 µg) plus 
10 µL of 0.5 M EDTA; and 0.5 M EDTA alone. Appropri-
ate control strains were included and synergistic results 
were interpreted as described [29, 32].
Multi‑locus sequence typing (MLST)
MLST assignments were determined using the scheme 
provided by Pasteur Institute MLST and Whole Genome 
MLST Database (https://www.pasteur.fr/mlst). MLST 
target genes, PCR primer sequences, and annealing tem-
peratures were all adopted from the database and opti-
mized. The resulting PCR amplicons were run on a 1% 
agarose gel to determine the amplicon size and quality, 
and the PCR product was purified using GeneJet PCR 
purification kit (ThermoFisher), and sent to GeneWiz, 
Inc. (GeneWiz) for Sanger sequencing. The allelic iden-
tification of the sequences and strain determination was 
performed using the Pasteur MLST database (http://
www.pubmlst.org/abaumannii/).
Biofilm formation assay
Biofilm production was determined using 96-well poly-
styrene plates as described by O’Toole et al., with minor 
modifications [33]. Briefly, overnight cultures were grown 
in LB broth at 37 °C in an aerobic incubator. The follow-
ing day, 200  µL LB broth diluted cultures (1:100) were 
added to multiple wells and the plates incubated at 37 °C 
in a static aerobic incubator for either 24 or 48 h. At the 
appropriate time the optical density was read at 595 nm, 
then each well received 30  µL of 0.1% Crystal Violet 
solution to incubate for 1 h at room temperature. After 
incubation, the plates were washed with tap water three 
times and allowed to dry at room temperature for 1  h. 
Then 250 µL of ethanol:acetone (4:1) solution was added 
to each well to solubilize the remaining stain. The optical 
density was then read at 570 nm, and the biofilm produc-
tion was quantified by taking the  OD570:OD590 ratio. The 
ratio was corrected with negative control (LB alone), and 
biofilm forming capability of the isolates considered if 
the  OD570:OD590 ratio was a positive value. Experiments 
were run in two separate assays with a total of sixteen 
replicates each.
Results
Characterization of isolates
A total of 26 CRAB isolates were analyzed in this study, 
all collected from Hahnemann Hospital. Sixteen isolates 
were collected during 2010–2011 (old isolates), and the 
additional 10 isolates were collected in 2015 (new iso-
lates). The relevant descriptive features are summarized 
in Table 1. The average age of all the patients from which 
the isolates were collected was 50.1 (± 17.7) years, with 
a range of 19–84 years. Of the 26 total patients 15 (57%) 
were male. A total of 14 (54%) patients were admitted in 
the ICU during the time of collection, and the other 12 
(46%) patients were being treated for various conditions 
in non-ICU in-patient rooms in the hospital. A total of 
12 (43%) patients’ infections were considered nosocomial 
in origin, in which the first positive A. baumannii culture 
was reported ≥ 48 h post-admission [34].
Antibiotic susceptibility
The findings of the antibiotic susceptibility testing for 
all isolates are showed in Additional file 3: Table S3. The 
antibiogram patterns of all 26 CRAB isolates by iso-
late groups (2010–2011 versus 2015), clinical source, 
and MLST sequence types are presented in Table 2. All 
26 (100%) of the CRAB isolates met the clinical defini-
tion of the MDR A. baumannii phenotype, defined as 
being non-susceptible to at least 3 classes of antibiotics 
[34]. All isolates (100%) were resistant or intermediately 
resistant to carbapenems (meropenem and imipenem), 
as well as Levofloxacin (fluoroquinolone). More than 80% 
of the isolates were resistant or intermediately resistant 
Table 1 Demographics of carbapenem-resistant A. bau-
mannii positive patients
Features 2010–2011 isolates 2015 isolates
Number of isolates 16 10
Average age of patient (yr) 47.8 ± 19.1 55.6 ± 15.1
Male (%) 62 50
ICU patients (%) 37 50
Nosocomial infections (%) 37 60
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to aminoglycosides, cephalosporins, extended-spectrum 
penicillins, and folate inhibitors.
Multi‑locus sequence typing (MLST)
MLST was performed for all 26 CRAB isolates as 
described in Methods. A total of 12 (46%) isolates were 
determined to be ST-229 and 14 (54%) were determined 
to be ST-2. In the 2010–2011 isolate group, 11 (68%) 
of the 16 isolates were determined to be members of 
ST-229, while the remaining 5 (32%) isolates were iden-
tified as ST-2. In the 2015 isolate group, 9 (90%) of the 
isolates were identified as strain 2, and only 1 (10%) were 
determined to be ST 229 (Additional file  4: Figure S1). 
The isolates and their MLST sequence types are summa-
rized in Table 3.
Extended‑spectrum β‑lactamase (ESBL) genotypic analysis
Table  3 summarizes all the ESBL genes explored in this 
study. All CRAB isolates, and A. baumannii controls car-
ried the Group D oxacillinase blaOXA-51-like gene (Addi-
tional file  4: Figure S1), while no isolates contained the 
blaOXA-24 or blaOXA-58-like gene. Two isolates, one from 
the 2010–2011 isolate group and one from the 2015 iso-
late group, possessed the blaOXA-40-like gene (Fig.  1). 
Both blaOXA-40-like positive isolates had the same MLST 
sequence type with a similar genotypic profile. Similarly, 9 
(34%) isolates had blaOXA-23-like genes (one from the 2010–
2011 isolates and eight from the 2015 isolates) had the 
similar genotypic profiles. All of the CRAB isolates con-
tained the Group A β-lactamase gene blaTEM, and 11 (42%) 
of the isolates had blaSHV. The blaSHV positive isolates 
were all ST-229, suggesting a similar clonal linage. All of 
the isolates were negative for other Group A β-lactamase 
genes including blaPER, blaVEB, as well as the most com-
monly reported clinical subtypes of blaKPC, and blaCTX-
M. Additionally all isolates were negative for all of the 
Group B metallo-β-lactamases (MBLs) genes tested which 
included, blaImp, blaVIM, blaGIM, blaSPM, blaSIM, blaDIM, and 
blaNDM-1. All of the CRAB isolates tested contained the 
Group C cephalosporinase blaampC gene, while 20 (76%) 
also possessed the cephalosporinase blaADC-7 gene.
Mobile genes and insertion sequences
As described by Koeleman et  al., the presence of mobile 
genetic elements is of particular interest as they provide 
strong evidence for the horizontal dissemination of anti-
biotic resistance genes [35]. The two mobile gene ele-
ments explored in this study were the class 1 integron 
cassette (ICA1) and three integrase coding genes (int123) 
as described in Hujer et al. [36]. A total of 11 (42%) of the 
CRAB isolates contained ICA1, and 21 (80%) of the isolates 
had int123. Only two isolates #58 (blaOXA-40-like positive) and 
#64 (blaOXA-23-like positive) from the 2010–2011 isolates were 
negative for both mobile gene elements, while all 10 (100%) 
of the 2015 CRAB isolates were positive for one or both of 
the mobile gene elements (Table 3). These data suggest that 
the majority of the CRAB isolates in present study may have 
ability to transfer genetic elements through integrons, and 
that these mobile elements may contain antibiotic resistance 
genes.
In addition, we detected IS elements in the promoter 
regions of several antibiotic resistance genes. A total of 
25 (96%) of the CRAB isolates examined in this study 
were found to have the ISAba1 element upstream of 
OXA-51 (Additional file 5: Figure S2; Table 3), and one 
negative isolate #58 also carried ISAba1 in the non-
promoter region of OXA-51 (this isolate also processes 
the blaOXA-40-like gene). In addition, ISAba1 was found 
upstream of the ampC cephalosporinases in 92% of the 
isolates, and upstream of the ADC-7 gene in 76% of the 
isolates.
Biofilm production
In vitro biofilm production assays were performed on all 
CRAB isolates (Fig. 1) with 9 of 26 (34%) showing varying 
degrees of biofilm production. Figure 1a shows the 2015 
isolates includes more biofilm producers than the 2010–
2011 isolates (p =  0.03). There was no significant asso-
ciation found between biofilm production and the source 
of the isolate (Fig. 1b). Evaluation of biofilm production 
between the two MLST strain types demonstrated that 
the ST-2 strains were significantly better biofilm produc-
ers than the ST-229 strains (p = 0.04) (Fig. 1c).
Discussion
The present study was undertaken to determine whether 
any patterns of resistance and fitness within our clinical 
CRAB isolate groups evolved or expanded over time. The 
unique aspect to this study is the two isolate groups we used 
were collected 4–5 years apart. This fact allowed us to have 
a look longitudinally at the genotypes and phenotypes of 
antibiotic-resistant A. baumannii isolates, and to potentially 
identify traits that make certain isolates successful patho-
gens under the selective pressures of a hospital setting.
From a clinical perspective, all the isolates examined 
in this study displayed the MDR phenotype [34]. We 
aimed to find the genetic mechanisms conferring these 
resistances in our isolates by exploring the presence of a 
large number of β-lactamase encoding genes. Metallo-β-
lactamase positive A. baumannii isolates are rare in the 
United States, and we did not find isolate carrying MBL 
gene; however globally, reports detecting their appear-
ance are increasing in frequency [37–39]. The Group A 
β-lactamases encoded by blaTEM and blaSHV genes has 
been shown to hydrolyze both penicillins, as well as first- 
and second- generation cephalosporins [40]. Interestingly 
Page 6 of 10Raible et al. Ann Clin Microbiol Antimicrob  (2017) 16:75 
Ta
b
le
 3
 P
C
R
 r
es
u
lt
s 
fo
r 
26
 C
R
A
B
 is
o
la
te
s
Pr
im
er
 s
et
s 
ta
rg
et
in
g 
β-
la
ct
am
as
e 
ge
ne
s 
(d
is
p
la
ye
d 
by
 A
m
b
le
r c
la
ss
), 
in
se
rt
io
n 
se
qu
en
ce
 (I
SA
ba
1)
, a
nd
 m
ob
ile
 g
en
e 
el
em
en
ts
. S
ou
rc
e 
(S
p 
sp
ut
um
, T
 ti
ss
ue
/w
ou
nd
, U
 u
rin
e,
 B
 b
lo
od
); 
M
IC
 m
er
op
en
em
 (≤
 2
 μ
g/
m
L 
= 
Se
ns
iti
ve
, ≥
 8
 μ
g/
m
L 
= 
Re
si
st
an
t)
; K
PC
 (K
PC
 s
ub
ty
p
es
 1
, 2
, 5
, 1
0)
; C
TX
 (C
TX
-M
 s
ub
ty
p
es
 1
, 2
 8
, 9
, 2
5)
; M
BL
 m
et
al
lo
-β
-la
ct
am
as
e 
(D
IM
, G
IM
, I
M
P,
 N
D
M
, S
IM
, S
PM
, V
IM
); 
ED
TA
 D
D
S 
do
ub
le
 d
is
k 
sy
ne
rg
y 
as
sa
y,
 IC
A
1 
cl
as
s 
1 
in
te
gr
on
 c
as
se
tt
e 
ar
ra
y,
 in
t1
23
, c
on
se
rv
ed
 re
gi
on
 o
f i
nt
eg
ra
se
s 
1,
 2
, a
nd
 3
. A
ll 
PC
R 
re
ac
tio
ns
 ru
n 
in
 d
up
lic
at
e 
w
ith
 p
ro
p
er
 c
on
tr
ol
 s
tr
ai
ns
Is
ol
at
e
So
ur
ce
M
IC
M
LS
T 
Ty
p
e
TE
M
SH
V
PE
R
K
PC
V
EB
C
TX
M
B
L
ED
TA
 
D
D
S
A
D
C
‑7
IS
ab
a1
  
+ 
A
D
C
‑7
am
p
C
IS
ab
a1
 +
  
am
p
C
O
X
A
‑2
3
O
X
A
‑2
4
O
X
A
‑4
0
O
X
A
‑5
1
IS
ab
a1
  
+ 
O
X
A
‑5
1
O
X
A
‑
58
IC
A
1
in
t1
23
22
Sp
16
22
9
+
+
–
–
–
–
–
–
–
–
+
+
–
–
–
+
+
–
+
+
25
Sp
16
22
9
+
+
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
+
+
28
T
8
2
+
–
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
–
+
32
U
32
22
9
+
+
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
+
+
39
Sp
16
22
9
+
+
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
+
+
42
T
16
22
9
+
+
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
+
+
51
T
16
22
9
+
+
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
+
+
52
U
16
22
9
+
+
–
–
–
–
–
–
+
+
+
–
–
–
–
+
+
–
+
+
56
U
32
22
9
+
+
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
+
+
57
U
8
2
+
–
–
–
–
–
–
–
–
–
+
+
–
–
–
+
+
–
–
+
58
T
>
 2
56
2
+
–
–
–
–
–
–
–
+
+
+
–
–
–
+
+
–
–
–
–
61
U
16
22
9
+
+
–
–
–
–
–
–
–
–
+
+
–
–
–
+
+
–
+
+
62
Sp
16
22
9
+
+
–
–
–
–
–
–
–
–
+
+
–
–
–
+
+
–
+
+
64
T
32
2
+
–
–
–
–
–
–
–
+
+
+
+
+
–
–
+
+
–
–
–
65
B
16
2
+
+
–
–
–
–
–
–
–
–
+
+
–
–
–
+
+
–
+
+
68
Sp
8
22
9
+
–
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
–
+
22
0
T
32
2
+
–
–
–
–
–
–
–
–
–
+
+
+
–
–
+
+
–
–
+
22
2
B
64
2
+
–
–
–
–
–
–
–
+
+
+
+
+
–
–
+
+
–
–
+
22
3
Sp
32
2
+
–
–
–
–
–
–
–
+
+
+
+
+
–
–
+
+
–
+
+
22
4
T
64
22
9
+
+
–
–
–
–
–
–
+
+
+
+
–
–
–
+
+
–
+
+
22
5
T
32
2
+
–
–
–
–
–
–
–
+
+
+
+
+
–
–
+
+
–
–
+
22
6
T
32
2
+
–
–
–
–
–
–
–
+
+
+
+
+
–
–
+
+
–
+
+
22
9
Sp
32
2
+
–
–
–
–
–
–
–
+
+
+
+
+
–
–
+
+
–
+
+
23
1
Sp
64
2
+
–
–
–
–
–
–
–
+
+
+
+
+
–
–
+
+
–
–
+
23
2
T
>
 2
56
2
+
–
–
–
–
–
–
–
+
+
+
+
–
–
+
+
+
–
–
+
23
5
T
32
2
+
–
–
–
–
–
–
–
+
+
+
+
+
–
–
+
+
–
–
+
Page 7 of 10Raible et al. Ann Clin Microbiol Antimicrob  (2017) 16:75 
there seems to be a distinction with regard to ST type 
with regard to possession of the blaSHV gene wherein the 
blaSHV gene was found in 10 (83%) of ST-229 isolates, 
and 1 (7%) of the ST-2 isolates. Although blaampC and 
blaADC-7 genes encode cephalosporinases were present, 
the later (blaADC-7 was predominant (in 76% of isolates), 
which have been shown to be inducible [41, 42].
The blaOXA-51-like allele is chromosomal and has been 
reported as an intrinsic gene of the A. baumannii spe-
cies [43]. Both the blaOXA-23-like and blaOXA-40-like genes 
can be either plasmid or chromosome borne, and have 
an increased risk of horizontal dissemination, resulting 
in increased rates of resistance in healthcare settings [44, 
45]. In our isolate groups, only 2 (7%) isolates contained 
the blaOXA-40-like gene; interestingly these two isolates dis-
play the greatest phenotypic resistance to meropenem 
(≥ 256 μg/mL), while 9 (34%) of our CRAB isolates pos-
sess the blaOXA-23-like gene, and displayed MICs between 
32–64  μg/mL. These two oxacillinase genes were only 
found in ST-2 isolates in among the 2010–2011 isolate 
group; but seem to have been successfully disseminated 
into the hospital setting overtime as they were found in 9 
(90%) of the 2015 isolate group.
A major concern in the healthcare community is the 
acquisition of genes such OXA-23-like and OXA-40-like 
through mobile genetic element transfers [46]. We did 
not determine whether these mobile elements such as 
integron-encoded integrase genes flank resistance genes, 
but their presence in majority (80%) of proposed CRAB 
suggests that those isolates are capable of acquiring and 
donating virulence genes by recombination.
An interesting finding from this study was the presence 
of IS elements upstream of several β-lactamase genes. It 
has been previously shown that the insertion of the IS 
element ISAba1 upstream of the OXA-51 gene changes 
the expression level leading to increased antimicrobial 
resistance [43]. Except isolate #58, which was co-carry-
ing blaOXA-40 like gene), every isolate examined in this 
study was found to have ISAba1 upstream of the blaOXA-
51-like gene (Additional file  5: Figure S2), and suggesting 
that the isolates may have additional mechanisms resist-
ance against carbopenem. The ISAba1 was also present 
in promoter region of blaampC gene (92%) and blaADC-7 
gene (76%) of the isolates, and suggest the overexpression 
of the downstream cephalosporinase genes resulting in 
an enhanced resistance phenotype.
MLST typing showed differing prevalence of the two 
STs of resistant strains of A. baumannii throughout 
the hospital over time. A comparison suggests that the 
majority of the isolates of 2010–2011 group were the 
members of ST-229, and only 5 (32%) isolates were ST-2, 
whereas interestingly, 90% of the isolates of 2015 group 
were ST-2, and only (10%) determined as ST-229. These 
data indicate over the course of 4–5 years that the ST-2 
has successfully replaced most of the ST-229 strains 
to become the predominant resistant type within our 
hospital.
Why is one strain type more successful than the 
other when it appears the two strain types share simi-
lar genetic resistance mechanisms? It has been previ-
ously reported that biofilm production is an important 
virulence factor for A. baumannii as it may aid coloni-
zation and survival on abiotic hospital environments 
[47]. Thus, we explored the ability of our CRAB isolates 
to produce biofilm on an abiotic (polystyrene) surface, 
to give an indication of how well these strains might 
colonize both medical equipment and objects in the 
clinical environment. We found that there were no sig-
nificant differences between the clinical source of the 
isolates or their ability to produce biofilms (Fig.  1b). 
Other studies using more clonally diverse strains have 
shown enhanced biofilm producing isolates derived 
Fig. 1 Biofilm production of CRAB isolates at 24 h (48 h data not shown) in 96-well polystyrene plate using Crystal Violet staining method. a Biofilm 
production with isolates grouped as old and new isolates (*p = 0.03). b Isolates grouped by clinical source exhibited non-significant value, may be 
due to lack of clonal heterogeneity. c CRAB isolates showing biofilm production, grouped by MLST sequence type/strain type (*p = 0.04)
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from urine and sputum cultures [48, 49]. Therefore, the 
non-significant result in our isolate group may be due 
to a lack of clonal heterogeneity. When we grouped our 
isolates by isolate groups (2010–2011 versus 2015) we 
found the 2015 isolate group had an enhanced ability 
to produce biofilm over the old isolates (Fig.  1a). Due 
to the predominance of ST-2 in the 2015 isolate group 
we explored biofilm production by MLST strain type, 
wherein the ST-2 showed an increased biofilm produc-
tion compared to ST-229 (Fig. 1c). Therefore, a possible 
explanation for the success of ST-2 over ST-229 may 
be its enhanced ability to produce biofilms resulting in 
a more effective colonization within the hospital, even 
when the two strains exhibit similar antibiotic resist-
ance phenotypes.
Conclusion
The temporal nature of the isolates used in this study pro-
vided a unique opportunity to epidemiologically monitor 
multi-drug-resistant A. baumannii isolates from the same 
hospital over time. We have shown that all of the CRAB 
isolates in our hospital belong to either MLST strain 
type ST-2 or ST-229 and that these two strain types most 
likely share similar mechanisms of resistance with pos-
sibly ISAba1-dependent overexpression of β-lactamase 
genes, resulting in an MDR phenotype. Interestingly over 
a 4–5 years’ timeframe the ST-2 type replaced the ST229 
type to become the predominate CRAB strain within the 
hospital which we believe is due to its enhanced ability 
to produce biofilms leading to improved colonization and 
survival on abiotic surfaces. To our knowledge, this is the 
first study to comparatively characterize the genetic and 
phenotypic properties of clinical MDR A. baumannii iso-
lates from a US hospital over an extended time frame.
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